Continuous signaling of CD79b and CD19 is required for the fitness of Burkitt lymphoma B cells

被引:48
|
作者
He, Xiaocui [1 ,2 ]
Klaesener, Kathrin [1 ,2 ]
Iype, Joseena M. [1 ,3 ]
Becker, Martin [1 ,4 ]
Maity, Palash C. [1 ,3 ]
Cavallari, Marco [1 ]
Nielsen, Peter J. [2 ]
Yang, Jianying [1 ,2 ]
Reth, Michael [1 ,2 ]
机构
[1] Univ Freiburg, Biol 3, BIOSS Ctr Biol Signaling Studies, Fac Biol,Dept Mol Immunol, Freiburg, Germany
[2] Max Planck Inst Immunobiol & Epigenet, Freiburg, Germany
[3] Uni Hosp Ulm, Inst Immunol, Ulm, Germany
[4] Helmholtz Zentrum Munchen, Munich, Germany
来源
EMBO JOURNAL | 2018年 / 37卷 / 11期
基金
欧洲研究理事会;
关键词
B-cell antigen receptor; Burkitt lymphoma; Cas9; CRISPR; survival signal; tumor fitness; CHRONIC LYMPHOCYTIC-LEUKEMIA; ANTIGEN RECEPTOR; IG-ALPHA; IMMUNE-RESPONSE; BAFF-R; BETA; IMMUNOGLOBULIN; SURVIVAL; PROTEIN; MICE;
D O I
10.15252/embj.201797980
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Expression of the B-cell antigen receptor (BCR) is essential not only for the development but also for the maintenance of mature B cells. Similarly, many B-cell lymphomas, including Burkitt lymphoma (BL), require continuous BCR signaling for their tumor growth. This growth is driven by immunoreceptor tyrosine-based activation motif (ITAM) and PI3 kinase (PI3K) signaling. Here, we employ CRISPR/Cas9 to delete BCR and B-cell co-receptor genes in the human BL cell line Ramos. We find that Ramos B cells require the expression of the BCR signaling component Ig (CD79b), and the co-receptor CD19, for their fitness and competitive growth in culture. Furthermore, we show that in the absence of any other BCR component, Ig can be expressed on the B-cell surface, where it is found in close proximity to CD19 and signals in an ITAM-dependent manner. These data suggest that Ig and CD19 are part of an alternative B-cell signaling module that use continuous ITAM/PI3K signaling to promote the survival of B lymphoma and normal B cells.
引用
收藏
页数:14
相关论文
共 50 条
  • [21] Potentiated B-Cell Antigen Receptor Signaling In Mantle Cell Lymphoma Is Associated With Overexpression Of Surface CD79B and IgM
    Myklebust, June Helen
    Brody, Joshua
    Alizadeh, Ash A.
    Czerwinski, Debra K.
    Kolstad, Arne
    Green, Michael R.
    Houot, Roch
    Delabie, Jan
    Kohrt, Holbrook E.
    Irish, Jonathan M.
    Levy, Ronald
    BLOOD, 2013, 122 (21)
  • [22] United we stand: Double targeting of CD79B and CD20 in diffuse large B-cell lymphoma
    Tarantelli, Chiara
    Bertoni, Francesco
    BRITISH JOURNAL OF HAEMATOLOGY, 2022, 199 (02) : 169 - 170
  • [23] Polatuzumab Vedotin, an Antibody-Drug Conjugate Targeting CD79b, Is a Highly Active Agent Against Burkitt Lymphoma and Primary Mediastinal B-Cell Lymphoma
    Audino, Anthony N.
    Barth, Matthew J.
    Tiwari, Aradhana
    Edani, Dina
    Ayello, Janet
    Harrison, Lauren
    Morris, Erin
    Hochberg, Jessica C.
    Goldman, Stanton
    Klein, Christian
    Cairo, Mitchell S.
    BLOOD, 2019, 134
  • [24] CD79b expression in B-cell chronic lymphocytic leukemia
    D'Arena, G
    Cascavilla, N
    Musto, P
    Bisogno, RC
    Pistolese, G
    Carotenuto, M
    HAEMATOLOGICA, 2000, 85 (05) : 556 - 557
  • [25] Analysis of the individual contributions of Igα (CD79a)- and Igβ (CD79b)-mediated tonic signaling for bone marrow B cell development and peripheral B cell maturation
    Fuentes-Panana, Ezequiel M.
    Bannish, Gregory
    Karnell, Fredrick G.
    Treml, John F.
    Monroe, John G.
    JOURNAL OF IMMUNOLOGY, 2006, 177 (11): : 7913 - 7922
  • [26] Chimeric antigen receptor T cells to target CD79b in B-cell lymphomas
    Chu, Fuliang
    Cao, Jingjing
    Liu, Jingwei
    Yang, Haopeng
    Davis, Timothy J.
    Kuang, Shao-qing
    Cheng, Xiaoyun
    Zhang, Zheng
    Karri, Swathi
    Vien, Long T.
    Bover, Laura
    Sun, Ryan
    Vega, Francisco
    Green, Michael
    Davis, Richard Eric
    Neelapu, Sattva S.
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2023, 11 (11)
  • [27] Targeting CAR T Resistance Due to CD19 Loss with CD79b-Specific CAR T Cells in B-Cells Malignancies
    Chu, Fuliang
    Weng, Jinsheng
    Kuang, Shao-Qing
    Cheng, Xiaoyun
    Cao, JingJing
    Liu, Jingwei
    Karri, Swathi
    Reddy, Adithi
    Neelapu, Sattva S.
    BLOOD, 2018, 132
  • [28] CD38/CD19: a lipid raft-dependent signaling complex in human B cells
    Deaglio, Silvia
    Vaisitti, Tiziana
    Billington, Richard
    Bergui, Luciana
    Omede, Paola
    Genazzani, Armando A.
    Malavasi, Fabio
    BLOOD, 2007, 109 (12) : 5390 - 5398
  • [29] IL-10 is Predominantly Produced by CD19(low)CD5(+) Regulatory B Cell Subpopulation: Characterisation of CD19 (high) and CD19(low) Subpopulations of CD5(+) B cells
    Lee, Jae Ho
    Noh, Joonyong
    Noh, Geunwoong
    Choi, Wahn Soo
    Lee, Sang Sun
    YONSEI MEDICAL JOURNAL, 2011, 52 (05) : 851 - 855
  • [30] Aberrant B cell receptor signaling from B29 (Igβ, CD79b) gene mutations of chronic lymphocytic leukemia B cells
    Gordon, MS
    Kato, RM
    Lansigan, F
    Thompson, AA
    Wall, R
    Rawlings, DJ
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2000, 97 (10) : 5504 - 5509